1Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis, 2000, 26 (2): 133-143.
2Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood,2001, 97 (5): 1392-1398.
3Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8(Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin' s lymphoma. Blood, 1997, 90 (6):2188-2195.
4Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase 1 multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Clin Oncol, 1997, 15 (10): 3266-3274.
5McLaughlin P. Grillo-Lopez AJ. Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Clin Oncol, 1998,16 (8): 2825-2833.
6Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Clin Oncol, 1999,17 (1): 268-276.
7Gianni AM, Cortelazzo S, Magni M, et al. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant,2002, 29 (Suppl 1): 10-13.
8Gisselbrecht C. In vivo purging and relapse prevention following ASCT.Bone Marrow Transplant, 2002, 29 (Suppl 1): 5-9.
9Mangel J, Buckstein B, lmrie K, et al. lmmunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol, 2002, 29 (Suppl 2): 56-69.
10Kosits C, Callaghan M. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma. Oncol Nuts Forum, 2000, 27 (1): 51-59.
3GZUZMAN M S,GRILLO-LOPEZ A J,WHITE C A,et al.Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric-anti-CD20 monoclonal antibody and CHOP chemotherapy[J].J Clin Oncol,1999,17(1):268-276.
4MARTINELLI G,LASZLO D,FERRERI A J,et al.Clinical activity of rituximab in gastricmargimal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter Pylori therapy[J].J Clin Oncol,2005,23(9):1979-1983.
5Yun J,Kim SJ,Kim JA,et al.Clinical features and treatment outcomes of non-Hodgkin′s lymphomas involving rare extranodal sites:a single-center experience[J].Acta Haematol,2010,123(1):48.
6Zwick C,Gleissner B,Pfreundschuh M.Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma[J].Clin Lymphoma Myeloma,2007,8(Suppl 2):S43.
7Wilson WH,Gutierrez M,O′Connor P,et al.The role of rituximab and chemotherapy in aggressive B-cell lymphoma:a preliminary report of dose-adjusted EPOCH-R[J].Semin Oncol,2002,29(1 Suppl 2):41.
8Kewalramani T,Zelenetz AD,Nimer SD,et al.Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma[J].Blood,2004,103(10):3684.
9Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin, 1998, 48 ( 1 ): 6-29.
10Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of rituxan (chimeric anti-CD20 ) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood, 2001,97 (5): 1392-1398.
